Stemline Therapeutics, Inc. (STML) Analysts See $-0.67 EPS

March 14, 2018 - By Ellis Scott

 Stemline Therapeutics, Inc. (STML) Analysts See $ 0.67 EPS
Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It is positive, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported.
Panagora Asset Management holds 26,010 shares or 0% of its portfolio. Northern Trust has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 286,147 shares. Voya Lc accumulated 11,069 shares or 0% of the stock. Knott David M holds 74,992 shares. 1,313 were reported by Ameritas Investment Prtn Inc. Victory Cap Management holds 0% or 1,858 shares in its portfolio. 35,816 were reported by California State Teachers Retirement Systems. Tower Rech Limited (Trc) holds 0% or 2,909 shares in its portfolio. Millennium Management Ltd reported 33,340 shares. Metropolitan Life Insurance Com accumulated 15,763 shares. 16,038 are held by Art Ltd Liability Co. Blackrock stated it has 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Baldwin Brothers Ma invested in 0.01% or 3,100 shares. Legal General Group Public Ltd Company holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 3,951 shares. Moreover, Fmr has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML).

Since December 15, 2017, it had 0 insider buys, and 11 sales for $1.47 million activity. Another trade for 3,027 shares valued at $50,097 was made by Hoberman Kenneth on Wednesday, March 7. Bergstein Ivan had sold 6,797 shares worth $112,558 on Wednesday, March 7.

Analysts expect Stemline Therapeutics, Inc. (NASDAQ:STML) to report $-0.67 EPS on March, 15.They anticipate $0.11 EPS change or 19.64 % from last quarter’s $-0.56 EPS. After having $-0.68 EPS previously, Stemline Therapeutics, Inc.’s analysts see -1.47 % EPS growth. The stock decreased 0.45% or $0.08 during the last trading session, reaching $16.67. About 6,898 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since March 14, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Stemline Therapeutics, Inc. (NASDAQ:STML) Ratings Coverage

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 13 analyst reports since November 10, 2015 according to SRatingsIntel. As per Tuesday, September 12, the company rating was maintained by H.C. Wainwright. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) earned “Buy” rating by H.C. Wainwright on Wednesday, November 1. The firm has “Buy” rating given on Wednesday, June 14 by Cowen & Co. The company was maintained on Wednesday, August 9 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Friday, November 10 with “Buy”. The company was maintained on Friday, February 2 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Monday, June 26. As per Friday, June 23, the company rating was maintained by Cowen & Co. The stock of Stemline Therapeutics, Inc. (NASDAQ:STML) has “Buy” rating given on Monday, June 26 by Jefferies. The stock has “Outperform” rating by Wedbush on Monday, February 6.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $483.11 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

Another recent and important Stemline Therapeutics, Inc. (NASDAQ:STML) news was published by Globenewswire.com which published an article titled: “Stemline Therapeutics Announces Proposed Public Offering of Common Stock” on January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.